P176-191 (HGH-frag)

P176-191 (HGH-frag) is presented here as a laboratory catalogue entry for research environments that need clear identification, labelled variants, and direct access to supporting records. The current listing includes 2 labelled variants: 5mg and 10mg. That structure keeps the page useful as both a procurement reference and an indexable resource covering stock visibility, pricing context, and documentation.

Within the wider Au Peptide Labs catalogue, P176-191 (HGH-frag) sits alongside HGH, Retatrutide, and Tesamorelin. Researchers often review neighbouring compounds before selecting a comparator or deciding which sequence belongs in a screening panel. Keeping those internal paths close to the product page improves traceability and helps laboratory buyers compare materials without relying on vague or consumer-style copy.

In research literature, P176-191 (HGH-frag) is generally treated as a growth-hormone-axis research peptide. Peptides in the GH-axis research class act primarily at two receptor targets: the growth-hormone-releasing hormone receptor (GHRHR), a class B GPCR that couples Gs to cAMP/PKA and GH gene transcription in somatotroph cell models; or the ghrelin/GH secretagogue receptor (GHSR-1a), a constitutively active class A GPCR whose agonism also triggers Gq-IP3 calcium flux in addition to Gs signalling. GHRH analogs (sermorelin, tesamorelin, CJC-1295) target GHRHR; ghrelin mimetics (GHRP-2, GHRP-6, ipamorelin) target GHSR-1a. CJC-1295 with DAC uses a reactive maleimide group to form a covalent thioether bond with albumin Cys34, extending half-life to days — an unusual mechanism studied in covalent protein-binding and pharmacokinetic assays. Ipamorelin is notable for GHSR-1a selectivity with minimal off-target ACTH or cortisol pathway stimulation in pituitary cell assays, distinguishing it from less selective GHRP-6.

Research panels in this class typically compare GHRHR versus GHSR-1a pathway contributions, examine how DAC versus non-DAC half-life extension changes receptor-occupancy kinetics, or profile selectivity differences between ipamorelin and non-selective secretagogues. The GH fragment AOD-9604 (residues 176–191 of the GH sequence) is separately relevant as a lipolytic fragment that activates β3-adrenergic receptor signalling in adipocyte assays without engaging the somatotropic axis or IGF-1R. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether P176-191 (HGH-frag) behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.

If a product-specific file is not attached to this listing, the wider COA library remains the correct reference point for current published documentation. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.

When teams compare P176-191 (HGH-frag) with HGH, Retatrutide, and Tesamorelin, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.